The Good, The Bad and the Ugly of CMO partnerships: A biotech perspective
The Good, The Bad and the Ugly of CMO partnerships: A biotech perspective https://csuiteold.c-suitenetwork.com/wp-content/uploads/2018/03/the-good-the-bad-and-the-ugly-of-cmo-partnerships-a-biotech-perspective.jpg 750 500 C-Suite Network https://csuiteold.c-suitenetwork.com/wp-content/uploads/2018/03/the-good-the-bad-and-the-ugly-of-cmo-partnerships-a-biotech-perspective.jpg
California-headquartered Ardelyx outsources all manufacturing, senior director of active pharmaceutical ingredient (API) engineering James Kanter told us in the lead up to his presentation at this month’s DCAT Week.
His talk, titled ‘The Good, the Bad and the Ugly’ discusses strategies for optimizing manufacturing and supply for emerging pharmaceutical companies.
According to Kanter, Ardelyx – which employs fewer than 100 staff – is too small to manufacture itself.
“There are so many CMOs out there that are very good at manufacturing,” he said.
“The fixed cost of having a manufacturing site is certainly not worth it, especially for small molecules.”
Once the company has developed its molecules to a certain level, it turns to outsourcing partners for clinical trials, and hopefully commercialization, he added.
Ardelyx develops small molecule compounds for hyperphosphatemia, and irritable bowel syndrome with constipation (IBS-C), for which it is in the process of writing a…
